Attached files
| file | filename |
|---|---|
| EX-23.3 - CONSENT OF WITHUMSMITH+BROWN, PC, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR FSD - Gemini Therapeutics, Inc. /DE | ea138289ex23-3_gemini.htm |
| EX-5.1 - OPINION OF GOODWIN PROCTER LLP - Gemini Therapeutics, Inc. /DE | ea138289ex5-1_gemini.htm |
| S-1/A - AMENDMENT NO. 1 TO FORM S-1 - Gemini Therapeutics, Inc. /DE | ea138289-s1a1_geminitherap.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 29, 2021, with respect to the financial statements of Gemini Therapeutics, Inc. included in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-253175) and related Prospectus of Gemini Therapeutics, Inc (f/k/a FS Development Corp) for the registration of 29,368,920 shares of its common stock.
| /s/ Ernst & Young LLP | |
| Boston, Massachusetts | |
| March 29, 2021 |